USPTO serial 85527461
BASILEA PHARMACEUTICA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MEYERS, MORGAN LAURA
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BASILEA PHARMACEUTICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Evan A. Raynes
Evan A. Raynes Symbus Law Group, LLC1775 K Street, NW, Suite 1150Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical ormedical laboratory use | ACTIVE | — |
| 005 | Pharmaceutical and veterinary products and preparations for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection,warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products andpreparations for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations for thetreatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary productsand preparations for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in thearea of allergy; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of anestesiology; Pharmaceutical and veterinary products and preparations for the treatment andprevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents | ACTIVE | — |
| 042 | Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Basilea Pharmaceutica AG
- Other trademarks owned by Basilea Pharmaceutica AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BASILEA PHARMACEUTICA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 12, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 12, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 11, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 10, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 3, 2016 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 3, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 3, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 15, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 14, 2015 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 5, 2015 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 5, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 3, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 2, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 30, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 30, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 4, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 3, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 30, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 10, 2014 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 10, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 6, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 2, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 2, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 2, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 28, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 5, 2013 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 10, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 10, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 7, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 6, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 6, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 6, 2013 | ALIE | ASSIGNED TO LIE | — |
| Aug 6, 2013 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 6, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 6, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 6, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 15, 2013 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 15, 2013 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 15, 2013 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jan 15, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 15, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 15, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 15, 2013 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jan 15, 2013 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Dec 10, 2012 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 10, 2012 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 14, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2012 | NWAP | NEW APPLICATION ENTERED | — |